Targeted Triumph: Precision Surgery for Breast Cancer

The SmartClip® technology for breast cancer surgery represents a significant advancement in our surgeons' ability to precisely localize and remove...

Revolutionizing Treatment for Node-Positive Melanoma: Neoadjuvant Therapy

Neoadjuvant therapy is advancing the fight against this aggressive form of skin cancer, creating a new standard of care.

SCOUTMD® Radar Localization: Revolutionizing Breast Cancer Surgery

The Breast Oncology Program at Moffitt Cancer Center is proud to be the first cancer center in the U.S. to offer SCOUTMD® Radar Localization.

Comprehensive Care for Endocrine Tumors at Moffitt

The Endocrine Oncology Program offers specialized care for both malignant and benign endocrine tumors using advanced techniques for complex cases.

Advancing Endometrial Cancer Treatment with Targeted Therapies

In June, the FDA approved the use of Durvalumab with carboplatin plus paclitaxel followed by single-agent durvalumab for patients with primary...

FDA Approval of Percutaneous Hepatic Perfusion Offers Patients New Hope

The FDA recently approved Percutaneous Hepatic Perfusion (PHP) with the HEPZATO KIT to treat metastatic uveal melanoma.

FDA Approves New Gene Therapy for Synovial Sarcoma

The FDA granted accelerated approval for Tecelra (afamitresgene autoleucel), a groundbreaking gene therapy for metastatic synovial sarcoma.

Q&A: Insights on Oral Cavity Cancer Treatment

Due to their aggressive nature, it's crucial to have treatment by an experienced surgeon and a multidisciplinary team from the first diagnosis of...

Minimally Invasive Surgery Advancements for Spinal Tumor Surgery

The Minimally Invasive Spine Oncology (MISO) program is patient-centered with a focus on the use of minimal access techniques for the treatment of...

Recent FDA Approvals for New Uses of Cellular Therapies

Recent advancements in cellular therapies, such as CAR T and TILs, have led to new FDA approvals for expanded uses.

Breakthroughs in Bispecific Antibodies & T-Cell Engagers: A New Era in Cancer Treatment

Bispecific T-cell engagers (BiTEs), a specialized subtype of bispecific antibodies (BsAbs), are antibody-based structures engineered to engage...

The Critical Role of Primary Care Physicians in Identifying Hematologic Malignancies

Multiple myeloma is a rare type of cancer that affects plasma cells, a type of white blood cell found in bone marrow that makes antibodies to help...

Q&A: Geniculate Artery Embolization (GAE)

GAE can be highly beneficial for patients who are not suitable candidates for joint replacement surgery.

Rectal Cancer Preservation: Balancing Cure and Quality of Life

The multidisciplinary team at Moffitt reviews every newly diagnosed rectal cancer within a specialized Rectal Cancer Tumor Board.

Understanding Mutations in the RAS Family of Genes

Moffitt has a strong interest to develop new therapies that can help patients with RAS mutations.

Clinical Perspectives